论文部分内容阅读
美国FDA于2007-12-18授予印度Matrix Laboratories,LTD生产的Viread(tenofovir disoproxil fumarate)300mg片剂仿制药试批准身份,与其他抗逆转录病毒药物联用治疗HIV感染。该项批复是FDA对核苷酸类逆转录酶抑制剂(nRTI)的首次试批准。nRTIs可阻断在HIV复制过程中起重要作用的逆转录酶。
The FDA approved the identity approval of a generic version of Viread (tenofovir disoproxil fumarate) 300mg tablet manufactured by India Matrix Laboratories, LTD on December 18, 2007 to treat HIV infection in combination with other antiretroviral drugs. This approval is the first FDA approval of a nucleotide reverse transcriptase inhibitor (nRTI). nRTIs block the reverse transcriptase that plays an important role in HIV replication.